Safety of the use of group A plasma in trauma

the STAT study

on behalf of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative and the STAT Study Investigators

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

BACKGROUND: Use of universally ABO-compatible group AB plasma for trauma resuscitation can be challenging due to supply limitations. Many centers are now using group A plasma during the initial resuscitation of traumatically injured patients. This study was undertaken to evaluate the impact of this practice on mortality and hospital length of stay (LOS). STUDY DESIGN AND METHODS: Seventeen trauma centers using group A plasma in trauma patients of unknown ABO group participated in this study. Eligible patients were group A, B, and AB trauma patients who received at least 1 unit of group A plasma. Data collected included patient sex, age, mechanism of injury, Trauma Injury Severity Score (TRISS) probability of survival, and number of blood products transfused. The main outcome of this study was in-hospital mortality differences between group B and AB patients compared to group A patients. Data on early mortality (≤24 hr) and hospital LOS were also collected. RESULTS: There were 354 B and AB patients and 809 A patients. The two study groups were comparable in terms of age, sex, TRISS probability of survival, and total number of blood products transfused. The use of group A plasma during the initial resuscitation of traumatically injured patients of unknown ABO group was not associated with increased in-hospital mortality, early mortality, or hospital LOS for group B and AB patients compared to group A patients. CONCLUSION: These results support the practice of issuing thawed group A plasma for the initial resuscitation of trauma patients of unknown ABO group.

Original languageEnglish (US)
Pages (from-to)1879-1884
Number of pages6
JournalTransfusion
Volume57
Issue number8
DOIs
StatePublished - Aug 1 2017

Fingerprint

Safety
Wounds and Injuries
Length of Stay
Resuscitation
Injury Severity Score
Hospital Mortality
Mortality
Survival
Trauma Centers
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Hematology

Cite this

on behalf of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative and the STAT Study Investigators (2017). Safety of the use of group A plasma in trauma: the STAT study. Transfusion, 57(8), 1879-1884. https://doi.org/10.1111/trf.14139

Safety of the use of group A plasma in trauma : the STAT study. / on behalf of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative and the STAT Study Investigators.

In: Transfusion, Vol. 57, No. 8, 01.08.2017, p. 1879-1884.

Research output: Contribution to journalArticle

on behalf of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative and the STAT Study Investigators 2017, 'Safety of the use of group A plasma in trauma: the STAT study', Transfusion, vol. 57, no. 8, pp. 1879-1884. https://doi.org/10.1111/trf.14139
on behalf of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative and the STAT Study Investigators. Safety of the use of group A plasma in trauma: the STAT study. Transfusion. 2017 Aug 1;57(8):1879-1884. https://doi.org/10.1111/trf.14139
on behalf of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative and the STAT Study Investigators. / Safety of the use of group A plasma in trauma : the STAT study. In: Transfusion. 2017 ; Vol. 57, No. 8. pp. 1879-1884.
@article{8109b3d5718c4cd0abe05e596959f635,
title = "Safety of the use of group A plasma in trauma: the STAT study",
abstract = "BACKGROUND: Use of universally ABO-compatible group AB plasma for trauma resuscitation can be challenging due to supply limitations. Many centers are now using group A plasma during the initial resuscitation of traumatically injured patients. This study was undertaken to evaluate the impact of this practice on mortality and hospital length of stay (LOS). STUDY DESIGN AND METHODS: Seventeen trauma centers using group A plasma in trauma patients of unknown ABO group participated in this study. Eligible patients were group A, B, and AB trauma patients who received at least 1 unit of group A plasma. Data collected included patient sex, age, mechanism of injury, Trauma Injury Severity Score (TRISS) probability of survival, and number of blood products transfused. The main outcome of this study was in-hospital mortality differences between group B and AB patients compared to group A patients. Data on early mortality (≤24 hr) and hospital LOS were also collected. RESULTS: There were 354 B and AB patients and 809 A patients. The two study groups were comparable in terms of age, sex, TRISS probability of survival, and total number of blood products transfused. The use of group A plasma during the initial resuscitation of traumatically injured patients of unknown ABO group was not associated with increased in-hospital mortality, early mortality, or hospital LOS for group B and AB patients compared to group A patients. CONCLUSION: These results support the practice of issuing thawed group A plasma for the initial resuscitation of trauma patients of unknown ABO group.",
author = "{on behalf of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative and the STAT Study Investigators} and Dunbar, {Nancy M.} and Yazer, {Mark H.} and Carey, {Patricia M.} and Christie, {John D.} and Fadeyi, {Emmanuel A.} and Fontaine, {Magali J.} and George, {Melissa R.} and Harm, {Sarah K.} and Hess, {John R.} and Karp, {Julie Katz} and Koepsell, {Scott A.} and Koepsell, {Scott A} and Liles, {Darla K.} and Murphy, {Michael F.} and Faisal Mukhtar and Novak, {Deborah J.} and Pagano, {Monica B.} and {Khan Parker}, {Lynette A.} and Passwater, {Michael E.} and Pelletier, {J. Peter R.} and Julie Staves and Stubbs, {James R.} and Robert Weinstein and Williams, {Lance A.} and Alyssa Ziman",
year = "2017",
month = "8",
day = "1",
doi = "10.1111/trf.14139",
language = "English (US)",
volume = "57",
pages = "1879--1884",
journal = "Transfusion",
issn = "0041-1132",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Safety of the use of group A plasma in trauma

T2 - the STAT study

AU - on behalf of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative and the STAT Study Investigators

AU - Dunbar, Nancy M.

AU - Yazer, Mark H.

AU - Carey, Patricia M.

AU - Christie, John D.

AU - Fadeyi, Emmanuel A.

AU - Fontaine, Magali J.

AU - George, Melissa R.

AU - Harm, Sarah K.

AU - Hess, John R.

AU - Karp, Julie Katz

AU - Koepsell, Scott A.

AU - Koepsell, Scott A

AU - Liles, Darla K.

AU - Murphy, Michael F.

AU - Mukhtar, Faisal

AU - Novak, Deborah J.

AU - Pagano, Monica B.

AU - Khan Parker, Lynette A.

AU - Passwater, Michael E.

AU - Pelletier, J. Peter R.

AU - Staves, Julie

AU - Stubbs, James R.

AU - Weinstein, Robert

AU - Williams, Lance A.

AU - Ziman, Alyssa

PY - 2017/8/1

Y1 - 2017/8/1

N2 - BACKGROUND: Use of universally ABO-compatible group AB plasma for trauma resuscitation can be challenging due to supply limitations. Many centers are now using group A plasma during the initial resuscitation of traumatically injured patients. This study was undertaken to evaluate the impact of this practice on mortality and hospital length of stay (LOS). STUDY DESIGN AND METHODS: Seventeen trauma centers using group A plasma in trauma patients of unknown ABO group participated in this study. Eligible patients were group A, B, and AB trauma patients who received at least 1 unit of group A plasma. Data collected included patient sex, age, mechanism of injury, Trauma Injury Severity Score (TRISS) probability of survival, and number of blood products transfused. The main outcome of this study was in-hospital mortality differences between group B and AB patients compared to group A patients. Data on early mortality (≤24 hr) and hospital LOS were also collected. RESULTS: There were 354 B and AB patients and 809 A patients. The two study groups were comparable in terms of age, sex, TRISS probability of survival, and total number of blood products transfused. The use of group A plasma during the initial resuscitation of traumatically injured patients of unknown ABO group was not associated with increased in-hospital mortality, early mortality, or hospital LOS for group B and AB patients compared to group A patients. CONCLUSION: These results support the practice of issuing thawed group A plasma for the initial resuscitation of trauma patients of unknown ABO group.

AB - BACKGROUND: Use of universally ABO-compatible group AB plasma for trauma resuscitation can be challenging due to supply limitations. Many centers are now using group A plasma during the initial resuscitation of traumatically injured patients. This study was undertaken to evaluate the impact of this practice on mortality and hospital length of stay (LOS). STUDY DESIGN AND METHODS: Seventeen trauma centers using group A plasma in trauma patients of unknown ABO group participated in this study. Eligible patients were group A, B, and AB trauma patients who received at least 1 unit of group A plasma. Data collected included patient sex, age, mechanism of injury, Trauma Injury Severity Score (TRISS) probability of survival, and number of blood products transfused. The main outcome of this study was in-hospital mortality differences between group B and AB patients compared to group A patients. Data on early mortality (≤24 hr) and hospital LOS were also collected. RESULTS: There were 354 B and AB patients and 809 A patients. The two study groups were comparable in terms of age, sex, TRISS probability of survival, and total number of blood products transfused. The use of group A plasma during the initial resuscitation of traumatically injured patients of unknown ABO group was not associated with increased in-hospital mortality, early mortality, or hospital LOS for group B and AB patients compared to group A patients. CONCLUSION: These results support the practice of issuing thawed group A plasma for the initial resuscitation of trauma patients of unknown ABO group.

UR - http://www.scopus.com/inward/record.url?scp=85020379555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020379555&partnerID=8YFLogxK

U2 - 10.1111/trf.14139

DO - 10.1111/trf.14139

M3 - Article

VL - 57

SP - 1879

EP - 1884

JO - Transfusion

JF - Transfusion

SN - 0041-1132

IS - 8

ER -